Product Description
Mechanisms of Action: IAP Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Breakthrough Therapy - Head and Neck Cancer *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Debiopharm International
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, France, Georgia, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Mexico, Netherlands, Norway, Poland, Portugal, Romania, Russia, Slovenia, Spain, Switzerland, Taiwan, Ukraine, United Kingdom, United States
Active Clinical Trial Count: 16
Highest Development Phases
Phase 3: Head and Neck Cancer|Squamous Cell Carcinoma
Phase 2: Breast Cancer|Cervical Cancer|Colorectal Cancer|Endometrial Cancer|Gastrointestinal Cancer|Oncology Solid Tumor Unspecified|Ovarian Cancer|Peritoneal Cancer|Small Cell Lung Cancer
Phase 1: Adenocarcinoma|Glioma|Healthy Volunteers|Non-Small-Cell Lung Cancer|Pancreatic Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Phase III xevinapant and radiotherapy in resected LA SCCHN | P3 |
Active, not recruiting |
Head and Neck Cancer|Squamous Cell Carcinoma |
2030-05-25 |
|
| MS202359_0002 | P3 |
Recruiting |
Head and Neck Cancer|Squamous Cell Carcinoma |
2030-02-28 |
|
| RAVINA | P2 |
Suspended |
Head and Neck Cancer|Squamous Cell Carcinoma |
2029-07-01 |
|
| IRB23-0294 | P1 |
Active, not recruiting |
Head and Neck Cancer|Squamous Cell Carcinoma |
2027-10-01 |